Literature DB >> 22734641

Norovirus P particle: a subviral nanoparticle for vaccine development against norovirus, rotavirus and influenza virus.

Ming Tan1, Xi Jiang.   

Abstract

Noroviruses (NoVs) are important pathogens causing epidemic acute gastroenteritis that affects millions of people worldwide. The protruding (P) domain of the NoV capsid protein, the surface antigen of NoV, forms a 24-mer subviral particle called the P particle that is an excellent candidate vaccine against NoVs. The P particles are easily produced in Escherichia coli, highly stable and highly immunogenic. Each P domain has three surface loops that can be used for foreign antigen presentation, making the P particles a useful platform for vaccine development against other infectious diseases. This article summarizes the discovery, structure, development and applications of the P particles as a vaccine against NoVs, as well as a vaccine platform against rotavirus, influenza virus and possibly other pathogens in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22734641      PMCID: PMC3514417          DOI: 10.2217/nnm.12.62

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  53 in total

Review 1.  Norovirus and its histo-blood group antigen receptors: an answer to a historical puzzle.

Authors:  Ming Tan; Xi Jiang
Journal:  Trends Microbiol       Date:  2005-06       Impact factor: 17.079

2.  Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice.

Authors:  H S Mason; J M Ball; J J Shi; X Jiang; M K Estes; C J Arntzen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

3.  Characterization of the influenza virus M2 integral membrane protein and expression at the infected-cell surface from cloned cDNA.

Authors:  S L Zebedee; C D Richardson; R A Lamb
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

4.  Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

Authors:  Wanli Liu; Peng Zou; Jian Ding; Yun Lu; Ying-Hua Chen
Journal:  Microbes Infect       Date:  2004-12-25       Impact factor: 2.700

5.  Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.

Authors:  J M Ball; D Y Graham; A R Opekun; M A Gilger; R A Guerrero; M K Estes
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  A fusion product of the complete Borrelia burgdorferi outer surface protein A (OspA) and the hepatitis B virus capsid protein is highly immunogenic and induces protective immunity similar to that seen with an effective lipidated OspA vaccine formula.

Authors:  Michael Nassal; Claudia Skamel; Peter A Kratz; Reinhard Wallich; Thomas Stehle; Markus M Simon
Journal:  Eur J Immunol       Date:  2005-02       Impact factor: 5.532

7.  Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

Authors:  P A Kratz; B Böttcher; M Nassal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  X-ray crystallographic structure of the Norwalk virus capsid.

Authors:  B V Prasad; M E Hardy; T Dokland; J Bella; M G Rossmann; M K Estes
Journal:  Science       Date:  1999-10-08       Impact factor: 47.728

9.  Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins.

Authors:  T Ito; O T Gorman; Y Kawaoka; W J Bean; R G Webster
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

10.  Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein.

Authors:  X Jiang; D O Matson; G M Ruiz-Palacios; J Hu; J Treanor; L K Pickering
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

View more
  31 in total

Review 1.  Burden of norovirus in healthcare facilities and strategies for outbreak control.

Authors:  A Kambhampati; M Koopmans; B A Lopman
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

Review 2.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

3.  Bioengineered Norovirus S60 Nanoparticles as a Multifunctional Vaccine Platform.

Authors:  Ming Xia; Pengwei Huang; Chen Sun; Ling Han; Frank S Vago; Kunpeng Li; Weiming Zhong; Wen Jiang; John S Klassen; Xi Jiang; Ming Tan
Journal:  ACS Nano       Date:  2018-09-25       Impact factor: 15.881

4.  Affinities of recombinant norovirus P dimers for human blood group antigens.

Authors:  Ling Han; Pavel I Kitov; Elena N Kitova; Ming Tan; Leyi Wang; Ming Xia; Xi Jiang; John S Klassen
Journal:  Glycobiology       Date:  2012-10-30       Impact factor: 4.313

5.  Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.

Authors:  Jacob Kocher; Tammy Bui; Ernawati Giri-Rachman; Ke Wen; Guohua Li; Xingdong Yang; Fangning Liu; Ming Tan; Ming Xia; Weiming Zhong; Xi Jiang; Lijuan Yuan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

6.  Identification and characterization of antibody-binding epitopes on the norovirus GII.3 capsid.

Authors:  Jackie E Mahar; Nicole C Donker; Karin Bok; Gert H Talbo; Kim Y Green; Carl D Kirkwood
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

7.  Identifying carbohydrate ligands of a norovirus P particle using a catch and release electrospray ionization mass spectrometry assay.

Authors:  Ling Han; Elena N Kitova; Ming Tan; Xi Jiang; John S Klassen
Journal:  J Am Soc Mass Spectrom       Date:  2013-10-05       Impact factor: 3.109

8.  Polyvalent complexes for vaccine development.

Authors:  Leyi Wang; Pengwei Huang; Hao Fang; Ming Xia; Weiming Zhong; Monica M McNeal; Xi Jiang; Ming Tan
Journal:  Biomaterials       Date:  2013-03-15       Impact factor: 12.479

9.  A dual vaccine candidate against norovirus and hepatitis E virus.

Authors:  Leyi Wang; Dianjun Cao; Chao Wei; Xiang-Jin Meng; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2013-11-27       Impact factor: 3.641

10.  A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.

Authors:  Ming Xia; Chao Wei; Leyi Wang; Dianjun Cao; Xiang-Jin Meng; Xi Jiang; Ming Tan
Journal:  Vaccine       Date:  2016-01-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.